Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. METHODS: In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis. RESULTS: After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group. CONCLUSIONS: Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combinations of VEGF-targeted agents with anti-PD-1 have demonstrated clinical benefi ts in endometrial carcinoma (pembrolizumab plus lenvatinib; refs.69, 70 ), RCC (pembrolizumab plus axitinib; nivolumab plus cabozantinib; avelumab plus axitinib), and hepatocellular carcinoma (atezolizumab plus bevacizumab; refs.[71][72][73][74][75].”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [71]
In the citing paper
“One study suggested that ICI-colitis correlated with particular strains of microbial flora colonization,19”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Self-citationMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
Self-citationHeng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133 · cited 1×
“IMDC risk score is determined by the total number of the following six risk factors that are present: Karnofsky performance-status score of less than 80 (on a scale from 0 to 100, with lower scores indicating greater disability(12)), a time from initial diagnosis to randomization of less than 1 year, a hemoglobin leve…”
MethodSelf-citationKarnofsky performance status revisited: reliability, validity, and guidelines.
Schag, C. C., Heinrich, R. L., & Ganz, P. A. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.3.187 · Cited by 1,517 · cited 1×
“Karnofsky performance-status scores range from 0 to 100, with lower scores indicating greater disability.(12) The programmed death ligand 1 (PD-L1) combined positive score was calculated as the number of PD-L1–positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of tumor cells, multip…”
MethodSystemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5561 · Cited by 787
Self-citationEscudier, B., Szczylik, C., Hutson, T. E., Demkow, T., Staehler, M., Rolland, F., Negrier, S., Laferriere, N., Scheuring, U. J., Cella, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3342 · Cited by 490
Self-citationSternberg, C. N., Hawkins, R. E., Wagstaff, J., Salman, P., Mardiak, J., Barrios, C. H., Zarba, J. J., Gladkov, O. A., Lee, E., Szczylik, C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.010 · Cited by 442
Self-citation
Research works printed but not linked: 1
- Noone AM, Howlader N, Krapcho M, et al., eds. SEER cancer statistics review (CSR), 1975-2015. Bethesda, MD: National Cancer Institute, 2018 (https://seer .cancer .gov/ csr/ 1975_2015/ ).
Cited by
Items 401–500 of 1,002
Mo, D., Luo, P., Huang, S., Wang, H., & Huang, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107281 · Cited by 60
Oliva, M., Chepeha, D. B., Araújo, D. V., Díaz-Mejía, J. J., Olson, P., Prawira, A., Spreafico, A., Bratman, S. V., Shek, T. L. T., de Almeida, J. R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003476 · Cited by 61
Incorvaia, L., Fanale, D., Badalamenti, G., Brando, C., Bono, M., Luca, I. D., Algeri, L., Bonasera, A., Corsini, L. R., Scurria, S., et al. (2020) · Cancers · doi:10.3390/cancers12113396 · Cited by 58
Montemagno, C., Hagege, A., Borchiellini, D., Thamphya, B., Rastoin, O., Ambrosetti, D., Iovanna, J., Rioux-Leclercq, N. C., Porta, C., Négrier, S., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1846901 · Cited by 61
“Indeed, immunotherapy has revolutionized the first-line treatment of mccRCC, with immune-oncology (IO) drug combinations (anti-PD-1 nivolumab and anti-CTLA-4 ipilimumab) in IMDC (International Metastatic RCC database Consortium) intermediate and poor-risk patients(3) or combination of VEGFR inhibitors and IO (axitinib…”
BackgroundSelf-citationAeppli, S., Schmaus, M., Eisen, T., Escudier, B. J., Grünwald, V., Larkin, J., McDermott, D. F., Oldenburg, J., Porta, C., Rini, B. I., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100030 · Cited by 61
“Sunitinib was again outperformed in the KEYNOTE426 trial, which tested the combination of pembrolizumab and axitinib, demonstrating a benefit in overall response rate (ORR), PFS and OS across all IMDC-risk groups.(8) Ipilimumab/nivolumab and pembrolizumab/axitinib were quickly incorporated into internationally accepte…”
ResultSelf-citationTherapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 62
“This combination also gained approval for use in RCC and MSI-H CRC.”
BackgroundInfluentialGao, L., Yang, X., Cheng, Y., & Zhu, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01173 · Cited by 58
Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma
Bacon, J. V. W., Annala, M., Soleimani, M., Lavoie, J., So, A., Gleave, M. E., Fazli, L., Wang, G., Chi, K. N., Kollmannsberger, C., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.12.018 · Cited by 58
Okoye, I., Xu, L., Walker, J. W. T., & Elahi, S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02555-2 · Cited by 61
Albiges, L. K., Barthélémy, P., Gross‐Goupil, M., Négrier, S., Needle, M. N., & Escudier, B. J. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.021 · Cited by 60
Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies
Benavente, S., Sánchez-García, A., Naches, S., LLeonart, M. E., & Lorente, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.582884 · Cited by 61
“Successful clinical evidence that the combination of ICB with antiangiogenic drugs has been recently reported in lung (127), renal (128, 129), and endometrial (130) cancer.”
BackgroundProcopio, G., Apollonio, G., Cognetti, F., Miceli, R., Milella, M., Mosca, A., Chiurì, V. E., Bearz, A., Morelli, F., Ortega, C., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.08.011 · Cited by 58
Vaishampayan, U. N., Schöffski, P., Ravaud, A., Borel, C., Peguero, J. A., Chaves, J. M., Morris, J. C., Kotecki, N., Šmakal, M., Zhou, D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0746-2 · Cited by 58
“…studies of anti – PD-1/PD-L1 antibodies in combination with targeted therapies as 1 L treatment for advanced or metastatic RCC were reported [14, 24 – 27]; this includes trials of avelumab combined with axitinib, particularly the recently reported phase III JAVELIN Renal 101 study, which showed…”
BackgroundInfluentialThe multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
Li, X., Li, M., Huang, M., Lin, Q., Fang, Q., Liu, J., Chen, X., Liu, L., Zhan, X., Shan, H., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113064 · Cited by 63
Bacterial outer membrane vesicle-based cancer nanovaccines
Gao, X., Feng, Q., Wang, J., & Zhao, X. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0452 · Cited by 64
Žvirblytė, J., Nainys, J., Juzėnas, S., Goda, K., Kubiliūtė, R., Dasevičius, D., Kinčius, M., Ulys, A., Jarmalaitė, S., & Mažutis, L. (2024) · Communications Biology · doi:10.1038/s42003-024-06478-x · Cited by 63
Hugaboom, M. B., Wirth, L. V., Street, K., Ruthen, N. G., Jegede, O. A., Schindler, N. R., Shah, V., Zaemes, J. P., Ahmar, N. E., Matar, S., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0991 · Cited by 63
Self-citationSuzuki, K., Terakawa, T., Furukawa, J., Harada, K., Hinata, N., Nakano, Y., & Fujisawa, M. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01528-5 · Cited by 58
“Our study showed that while a high NLR was associated with a poor OS, a poor risk according to the IMDC classification, which was established in the TKI era, was not associated with a poor OS.”
BackgroundInfluentialTargeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting
Aggen, D. H., Drake, C. G., & Rini, B. I. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3323 · Cited by 60
“In the context of kidney cancer, the PD-1– specific therapies nivolumab (2, 3) and pembrolizumab (4), as well as the PD-L1 antibody avelumab (5) are FDA-approved in combination with other therapies for metastatic renal cell carcinoma (RCC).”
BackgroundSelf-citationNégrier, S., Rioux-Leclercq, N. C., Ferlay, C., Gross‐Goupil, M., Gravis, G., Geoffrois, L., Chevreau, C., Boyle, H. J., Rolland, F., Blanc, E., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.001 · Cited by 57
“This combination should be further investigated in patients with mPRCC (29;30).”
BackgroundHarnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
Maia, M. C., Salgia, M. M., & Pal, S. K. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0297-9 · Cited by 62
Chang, W. H., & Lai, A. G. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.011 · Cited by 55
Makunts, T., Saunders, I. M., Cohen, I. V., Li, M., Moumedjian, T., Issa, M. A., Burkhart, K., Lee, P., Patel, S. P., & Abagyan, R. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-96467-5 · Cited by 59
Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma
Mantia, C. M., & McDermott, D. F. (2019) · Cancer · doi:10.1002/cncr.32361 · Cited by 59
“Twelve percent of patients in the atezolizumab plus bevacizumab arm and 8% of those in the sunitinib arm had to discontinue treatment because of AEs.41 The recently published KEYNOTE-426 study (Study to Evaluate the Efficacy and Safety of Pembrolizumab [MK-3475] in Combination With Axitinib Versus Sunitinib Monotherap…”
BackgroundInfluentialTung, I., & Sahu, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.707214 · Cited by 57
“The phase III trial, Keynote-426 delivered promising results for the use of PD-1 inhibitor pembrolizumab and anti-VEGF agent axitinib in first-line treatment for metastatic ccRCC (19, 20, 28).”
BackgroundA single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma
Kourtis, N., Wang, Q., Wang, B., Oswald, E. M., Adler, C., Cherravuru, S., Malahias, E., Zhang, L., Golubov, J., Wei, Q., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00391-0 · Cited by 58
Rager, T., Eckburg, A., Patel, M., Qiu, R., Gantiwala, S., Dovalovsky, K., Fan, K. D., Lam, K., Roesler, C., Rastogi, A., et al. (2022) · Cancers · doi:10.3390/cancers14153779 · Cited by 59
“Axitinib is used to treat renal cell carcinoma, and bevacizumab is used to treat cervical cancer [114,115].”
BackgroundFerrarotto, R., de Sousa, L. G., Feng, L., Mott, F. E., Blumenschein, G. R., Altan, M., Bell, D., Bonini, F., Li, K., Marques-Piubelli, M. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02221 · Cited by 64
“Consistently, VEGFR MKI combined with PD-1/PD-L1 inhibitors have shown higher efficacy than single-agent VEGFR MKI and have become the standard-of-care treatment for renal cell carcinoma and endometrial carcinoma.(23,24)”
BackgroundGuo, C. W., Alexander, M., Dib, Y., Lau, P. K. H., Weppler, A. M., Au‐Yeung, G., Lee, B., Khoo, C. C. H., Mooney, D., Joshi, S. B., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.009 · Cited by 56
“Increasigly, these agents are combined to exploit potential synergistic immune-modulation[3-6].”
BackgroundThe application of 3D bioprinting in urological diseases
Xu, K., Han, Y., Huang, Y., Wei, P., Yin, J., & Jiang, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100388 · Cited by 62
Procopio, G., Claps, M., Pircher, C. C., Porcu, L., Sepe, P., Guadalupi, V., Giorgi, U. D., Bimbatti, D., Nolè, F., Carrozza, F., et al. (2022) · Tumori Journal · doi:10.1177/03008916221138881 · Cited by 58
Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle
Wattenberg, M. M., & Beatty, G. L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.002 · Cited by 59
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Louedec, F. L., Leenhardt, F., Marin, C., Chatelut, É., Evrard, A., & Ciccolini, J. (2020) · Vaccines · doi:10.3390/vaccines8040632 · Cited by 62
“For example, axitinib associated with pembrolizumab [108] or avelumab [109] increased survival in advanced renal-cell carcinoma compared to sunitinib.”
BackgroundImmune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
Lavacchi, D., Pellegrini, E., Palmieri, V. E., Doni, L., Mela, M. M., Maida, F. D., Amedei, A., Pillozzi, S., Carini, M., & Antonuzzo, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134691 · Cited by 57
“With extended follow-up [26] (median follow-up 32.”
BackgroundROS Scavenging Nanozyme Modulates Immunosuppression for Sensitized Cancer Immunotherapy
Mo, W., Liu, S., Zhao, X., Wei, F., Li, Y., Sheng, X., Cao, W., Ding, M., Zhang, W., Chen, X., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300191 · Cited by 65
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tunger, A., Sommer, U. J., Wehner, R., Kubasch, A. S., Grimm, M., Bachmann, M. P., Platzbecker, U., Bornhäuser, M., Baretton, G. B., & Schmitz, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101534 · Cited by 55
Dutcher, J. P., Flippot, R., Fallah, J., & Escudier, B. J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280817 · Cited by 61
Dougan, M. L., Blidner, A. G., Choi, J. N., Cooksley, T., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., Johnson, D. B., Shannon, V. R., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05707-3 · Cited by 57
Khan, K. A., Wu, F. T. H., Cruz‐Muñoz, W., & Kerbel, R. S. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201708253 · Cited by 56
Xu, Y., Liao, W., Luo, Q., Yang, D., & Pan, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.761046 · Cited by 68
“These agents have become effective standard therapies in several advanced malignancies, including melanoma (6–8), Merkel cell carcinoma (9), urological cancers (10), non-small cell lung cancer (11), mis-match repair-deficient”
BackgroundChen, R., Li, Q., Xu, S., Ye, C., Tian, T., Jiang, Q., Shan, J., & Ruan, J. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02435-4 · Cited by 57
French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer
Bigot, P., Barthélémy, P., Boissier, R., Khene, Z., Pettenati, C., Bernhard, J., Corréas, J.-M., Doumerc, N., Gimel, P., Ingels, A., et al. (2022) · The French Journal of Urology · doi:10.1016/j.purol.2022.07.146 · Cited by 56
Yin, X., Wang, Z., Wang, J., Xu, Y., Kong, W., & Zhang, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1933332 · Cited by 69
Lee, S.-Y., Shim, H. S., Ahn, B., Lim, S. M., Kim, H. R., Cho, B. C., & Hong, M. H. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03052-w · Cited by 55
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 64
Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers
Chiaravalli, M., Spring, A., Agostini, A., Piro, G., Carbone, C., & Tortora, G. (2022) · Cells · doi:10.3390/cells11193033 · Cited by 55
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
Martin, E. D., Fulgenzi, C. A. M., Celsa, C., Laurent-Bellue, A., Torkpour, A., Lombardi, P., D’Alessio, A., & Pinato, D. J. (2024) · Gut · doi:10.1136/gutjnl-2024-332125 · Cited by 57
Puca, E., Probst, P., Stringhini, M., Murer, P., Pellegrini, G., Cazzamalli, S., Hutmacher, C., Gouyou, B., Wulhfard, S., Matasci, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32603 · Cited by 51
Sheng, I. Y. F., & Ornstein, M. C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202017 · Cited by 53
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
Tucker, M. D., & Rini, B. I. (2020) · Cancers · doi:10.3390/cancers12092662 · Cited by 56
“KEYNOTE-426 [9,10] Pembrolizumab + axitinib vs.”
BackgroundInfluentialSelf-citationTumor Cell–Derived TGFβ1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA
Wu, P., Geng, B., Chen, Q., Zhao, E., Liu, J., Sun, C., Zha, C., Shao, Y., You, B., Zhang, W., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0113 · Cited by 54
“Our findings reveal a mechanism of increased PD-1 expression induced by TGFb1 via upregulation of SRSF3/5 expression and provide evidence that patients with ccRCC may obtain clinical benefit from immune checkpoint blockade (56, 57).”
BackgroundCurrent Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma
Jian, Y., Yang, K., Sun, X., Zhao, J. J., Huang, K., Al-Danakh, A., Xu, Z., Wu, H., Xu, Q., Zhang, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.639636 · Cited by 60
“(155) investigated whether pembrolizumab in combination with axitinib achieved better outcomes in patients with advanced renal cell carcinoma previously untreated than sunitinib.”
BackgroundResistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 55
Golkaram, M., Kuo, F., Gupta, S., Carlo, M. I., Salmans, M., Vijayaraghavan, R., Tang, C., Makarov, V., Rappold, P. M., Blum, K. A., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01146-3 · Cited by 51
Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
Alonso‐Gordoa, T., García‐Bermejo, L., Grande, E., Garrido, P., Carrato, A., & Molina‐Cerrillo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081901 · Cited by 56
“The first one is the MK426 trial that randomized 861 patients with metastatic ccRCC to receive treatment with pembrolizumab 200 mg plus axitinib 5 mg/12 h versus sunitinib 50 mg/24 h four weeks on/two weeks off [115].”
BackgroundInfluentialCurrent State of Systemic Therapies for Advanced Renal Cell Carcinoma
Gulati, S., & Vaishampayan, U. N. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0892-1 · Cited by 58
Chakiryan, N. H., Jiang, D. D., Gillis, K. A., Green, E., Hajiran, A. J., Hugar, L. A., Zemp, L. W., Zhang, J., Jain, R., Chahoud, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.11329 · Cited by 53
Wang, J., Zou, Y., Du, B., Li, W., Yu, G., Li, L., Zhou, L., Gu, X., Song, S., Liu, Y., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03958-4 · Cited by 51
Hack, S. P., Verret, W. J., Mulla, S. M., Liu, B., Wang, Y., Macarulla, T. M., Ren, Z., El-Khoueiry, A. B., & Zhu, A. X. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211036544 · Cited by 51
McGregor, B. A., Mortazavi, A., Cordes, L. M., Salabao, C., Vandlik, S., & Apolo, A. B. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102333 · Cited by 56
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 53
The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
Garje, R., An, J., Greco, A., Vaddepally, R. K., & Zakharia, Y. (2020) · Cancers · doi:10.3390/cancers12010143 · Cited by 50
“KEYNOTE-426 [14] 861 Pembrolizumab + axitinib vs.”
MethodPignot, G., Thiery-Vuillemin, A., Albiges, L. K., Walz, J. C., Lang, H., Balssa, L., Parier, B., Geoffrois, L., Bensalah, K., Schlürmann, F., et al. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.07.002 · Cited by 49
Self-citationChen, X., Xu, H., Chen, X., Xu, T., Tian, Y., Wang, D., Guo, F., Wang, K., Jin, G., Li, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01773-9 · Cited by 56
Emerging therapeutic agents for genitourinary cancers
Zarrabi, K. K., Paroya, A., & Wu, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0780-z · Cited by 51
“Once again, toxicities were comparable between the two arms [86].”
BackgroundTherapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy
Jones, T. M., Carew, J. S., & Nawrocki, S. T. (2020) · Cancers · doi:10.3390/cancers12051185 · Cited by 51
Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma
Attalla, K., Weng, S., Voss, M. H., & Hakimi, A. A. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.002 · Cited by 58
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
Carreau, N. A., Pail, O., Armand, P. A., Merryman, R. W., Advani, R. H., Spinner, M. A., Herrera, A. F., Chen, R., Tomassetti, S., Ramchandren, R., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0167 · Cited by 58
“In lung cancer and renal cell carcinoma, the addition of immunotherapy to chemotherapy and targeted agents has shown superior results to chemotherapy alone [28, 29].”
BackgroundLin, E., Liu, X., Liu, Y., Zhang, Z., Xie, L., Tian, K., Liu, J., & Yu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653358 · Cited by 59
“Several phase III clinical trials showed that PD-1/PD-L1 inhibitors combined with anti-angiogenic agents significantly improved survival and therapeutic response in untreated patients with advanced ccRCC compared with anti-angiogenic monotherapy (70, 71, 76).”
BackgroundGan, C. L., Stukalin, I., Meyers, D. E., Dudani, S., Grosjean, H. A. I., Dolter, S., Ewanchuk, B. W., Goutam, S., Sander, M. S., Wells, J. C., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.004 · Cited by 50
Yang, Q., Chen, T., Wang, S., Zhang, X., & Yao, Z. (2020) · Angiogenesis · doi:10.1007/s10456-020-09716-y · Cited by 50
Davidsson, S., Fiorentino, M., Giunchi, F., Eriksson, M., Erlandsson, A., Sundqvist, P., & Carlsson, J. (2020) · European Urology Open Science · doi:10.1016/j.euros.2020.06.003 · Cited by 49
“Inhibition of different immune checkpoints, including CTLA-4, PD-1, and PD-L1, has shown remarkable impact in the treatment of cancer patients with solid tumors, including RCC [28].”
BackgroundRizzo, M., Varnier, L., Pezzicoli, G., Pirovano, M., Cosmai, L., & Porta, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.990568 · Cited by 53
“Several clinical trials tested ICIs in combination with VEGFR-TKIs, and results so far are showing unprecedented response rates and survival benefits across all patients’ risk groups (12, 13).”
BackgroundResultZhou, X., Khan, S. H., Huang, D., & Li, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938470 · Cited by 57
Patel, J. S., Woo, Y., Draper, A., Jansen, C. S., Carlisle, J. W., Innominato, P. F., Lévi, F., Dhabaan, L., Master, V. A., Bilen, M. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008011 · Cited by 55
Tumor angiogenesis and anti-angiogenic therapy
Guo, Z., Xu, J., Sun, X., Sun, S., Yang, Y., & Cao, Y. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003231 · Cited by 56
“Similarly, the ate-zolizumab–axitinib combination markedly improved PFS compared with sunitinib for treating metastatic RCC. [113] The combination of sunitinib with nivolumab (an anti-PD-1 antibody) or ipilimumab (an anti-CTLA-4 antibody) also had greater therapeutic efficacy in RCC relative to…”
BackgroundKobayashi, Y., Kushihara, Y., Saito, N., Yamaguchi, S., & Kakimi, K. (2020) · Cancer Science · doi:10.1111/cas.14621 · Cited by 60
Khanna, P., Soh, H. J., Chen, C.-H., Saxena, R., Amin, S., Naughton, M., Joslin, P. M. N., Moore, A., Bakouny, Z., O'Callaghan, C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc0170 · Cited by 49
Rose, A. A. N., Armstrong, S. M., Hogg, D., Butler, M. O., Saibil, S. D., Arteaga, D. P., Muniz, T. P., Kelly, D., Ghazarian, D., King, I. F. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001642 · Cited by 51
Hetero-bivalent agents targeting FAP and PSMA
Boinapally, S., Lisok, A., Lofland, G., Minn, I., Yan, Y., Jiang, Z., Shin, M. J., Merino, V. F., Zheng, L., Brayton, C. F., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05933-3 · Cited by 51
“Antivascular agents are used in treating ccRCC, more recently in combination with immune checkpoint inhibitors [53], suggesting that targeting the neovasculature – with a radiotheranostic – may enable tumor growth control.”
BackgroundResponse to systemic therapy in fumarate hydratase–deficient renal cell carcinoma
Carril-Ajuria, L., Colomba, É., Cerbone, L., Romero, C., Crouzet, L., Laguerre, B., Thibault, C., Vicier, C., de Velasco, G., Fléchon, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.009 · Cited by 51
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 51
“To date, pembrolizumab therapy has been licensed in many cancers (27, 30, 58, 59) and was often conducted primarily in patients with PD-L1-positive disease (31, 34).”
BackgroundZhang, G., Chen, X., Fang, J., Tai, P., Chen, A., & Cao, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954440 · Cited by 75
“In recent years, researchers have found that targeted therapy combined with immunotherapy has beneficial treatment effects and good prospects in patients with advanced KIRC, and has shown a trend of gradually replacing targeted therapy alone (9).”
BackgroundHuang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 52
Pal, K., Madamsetty, V. S., Dutta, S. K., Wang, E., Angom, R. S., & Mukhopadhyay, D. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0105-2 · Cited by 55
“Moreover, the combination of Axitinib with either Avelumab (a programmed death ligand 1 inhibitor) or Pembrolizumab (a programmed death1 inhibitor) exhibited superior progression-free survival and objective response rate over Sunitinib in two distinct large phase III trials.(56,57) Significant improvement in overall s…”
BackgroundUdayakumar, D., Zhang, Z., Xi, Y., Dwivedi, D. K., Fulkerson, M., Haldeman, S., McKenzie, T., Yousuf, Q., Joyce, A., Hajibeigi, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0706 · Cited by 68
“Angiogenic and immunogenic pathway activation likely coexist in many tumors and combination therapy with pembrolizumab (IO) and axitinib (AA) in patients with advanced kidney cancer demonstrated an impressive 59% objective response rate across all risk groups (22).”
BackgroundMotzer, R. J., Schmidinger, M., Eto, M., Suárez, C., Figlin, R. A., Liu, Y., Perini, R. F., Zhang, Y., & Heng, D. Y. (2023) · Future Oncology · doi:10.2217/fon-2022-0802 · Cited by 55
Self-citationEHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
Pan, Y., Shu, G., Fu, L., Huang, K., Zhou, X., Gui, C., Liu, H., Jin, X., Chen, M., Li, P., et al. (2023) · Advanced Science · doi:10.1002/advs.202206792 · Cited by 47
Self-citationZhang, Z., Pan, Q., Lu, M., & Zhao, B. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102156 · Cited by 49
Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application
Li, A., & Fang, J. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230025 · Cited by 55
T cell exhaustion in human cancers
Kang, K., Lin, X., Chen, P., Liu, H., Liu, F., Xiong, W., Li, G., Yi, M., Li, X., Wang, H., et al. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189162 · Cited by 56
Verbiest, A., Renders, I., Caruso, S., Couchy, G., Job, S., Laenen, A., Verkarre, V., Rioux-Leclercq, N. C., Schöffski, P., Vano, Y. A., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.05.009 · Cited by 48
Buonerba, C., Dolce, P., Iaccarino, S., Scafuri, L., Verde, A., Costabile, F., Pagliuca, M., Morra, R. P., Riccio, V., Ribera, D., et al. (2020) · Cancers · doi:10.3390/cancers12020408 · Cited by 47
“[18,23] Pembro + Axi 432 51 15,1; (12,6–17,7) 0,69; (0,57–0,84) 0,29; (0,54–1) 0,53; (0,38–0,74) 0,58; (0,21–1,59) 59,3 58,8 5,8 11,8 Sun 429 54 11,1; (8,7–12,5) 8,4 - 35,7 31,5 1,9 0”
McGregor, B. A., Gordon, M. S., Flippot, R., Agarwal, N., George, S., Quinn, D. I., Rogalski, M., Hawthorne, T. R., Keler, T., & Choueiri, T. K. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00945-y · Cited by 46
Anti-angiogenesis: Opening a new window for immunotherapy
Guo, F., & Cui, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118163 · Cited by 49
Choueiri, T. K., Atkins, M. B., Rose, T. L., Alter, R. S., Ju, Y., Niland, K., Wang, Y., Arbeit, R. D., Parasuraman, S., Gan, L., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01058-2 · Cited by 49
Self-citationImpact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review
Indini, A., Rijavec, E., Ghidini, M., Tomasello, G., Cattaneo, M., Barbin, F., Bareggi, C., Galassi, B., Gambini, D., & Grossi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052628 · Cited by 50
Barroso‐Sousa, R., Keenan, T. E., Li, T., Tayob, N., Trippa, L., Pastorello, R., Richardson, E. T., Dillon, D. A. R., Amoozgar, Z., Overmoyer, B. A., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00287-9 · Cited by 49
Targeted therapy for metastatic renal cell carcinoma
Hofmann, F., Hwang, E. C., Lam, T. B. L., Bex, A., Yuan, Y., Marconi, L. S., & Ljungberg, B. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012796.pub2 · Cited by 53
Tumor vessel co-option: The past & the future
Cuypers, A., Truong, A.-C. K., Becker, L. M., Saavedra-García, P., & Carmeliet, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.965277 · Cited by 50
Metadata
- Authors
- Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., Vynnychenko, I., Kryzhanivska, A., Bondarenko, I., Azevedo, S. J., Borchiellini, D., Szczylik, C., Markus, M., McDermott, R. S., Bedke, J., Tartas, S., Chang, Y.-H., Tamada, S., Shou, Q., Perini, R. F., Chen, M., Atkins, M. B., & Powles, T.
- Affiliations
- Fox Chase Cancer Center (US)
- From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) — all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Rini, Brian I.
- Plimack, Elizabeth R.
- Stus, Viktor
- Gafanov, Rustem
- Nosov, Dmitry
- Pouliot, Frédéric
- Alekseev, Boris
- Soulières, Denis
- Melichar, Bohuslav
- Vynnychenko, Ihor
- Kryzhanivska, Anna
- Bondarenko, Igor
- Borchiellini, Delphine
- Szczylik, Cezary
- Bedke, Jens
- Tamada, Satoshi
- Perini, Rodolfo F.
- Atkins, Michael B.
- Powles, Thomas
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-21
- Volume
- 380
- Issue
- 12
- Pages
- 1116-1127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2913745075
- Cited by
- 3,403
- References
- 23
- Citations by year
- 2026: 269 · 2025: 323 · 2024: 431 · 2023: 440 · 2022: 589 · 2021: 597 · 2020: 532 · 2019: 220
- FWCI
- 357.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Oncourology (Russian Society of Oncourologists) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Keywords
- pembrolizumab, axitinib, sunitinib, immune checkpoint inhibitors, PD-1 inhibitors, PD-L1 expression, overall survival, progression-free survival, objective response rate, first-line therapy, adverse events, immune-related adverse events, tyrosine kinase inhibitors, IMDC risk groups
- MeSH terms
- Sunitinib, Axitinib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Survival Rate, Single-Blind Method, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.